

Lao PDR

Support for Vaccine: Measles Rubella This Decision Letter sets out the Programme Terms of a Programme.

1. Country:	Lao PDR														
2. Vaccine grant number:	1720-LAO-18b-X, 1720-LAO-18e-X, 20-LAO-18h-X														
3. Date of Decision Letter:	30-Sep-2019														
4. Date of the Partnership Framework Agreement (PFA):	6/7/2013														
5. Programme title:	New Vaccine Support (NVS), Measles Rubella, 2D Routine														
6. Vaccine type:	Measles Rubella														
7. Requested product presentation and formulation of vaccine:	MR 5-LYO														
8. Programme Duration:¹	2018-2020														
9. Programme Budget (indicative):²	(subject to the terms of the PFA, if applicable)														
	2018-2019	2020	Total²												
Programme Budget (US\$)	445,090	120,000	565,090												
10. Vaccine introduction grant:	Not applicable														
	<table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th colspan="3">Approval</th> </tr> <tr> <th style="width: 15%;">Year</th> <th style="width: 45%;">Grant Number</th> <th style="width: 40%;">Amount (US\$)</th> </tr> </thead> <tbody> <tr> <td>2013</td> <td>13-LAO-08e-Y</td> <td style="text-align: right;">150,000</td> </tr> <tr> <td>2017</td> <td>17-LAO-08k-Y</td> <td style="text-align: right;">149,330</td> </tr> </tbody> </table>			Approval			Year	Grant Number	Amount (US\$)	2013	13-LAO-08e-Y	150,000	2017	17-LAO-08k-Y	149,330
Approval															
Year	Grant Number	Amount (US\$)													
2013	13-LAO-08e-Y	150,000													
2017	17-LAO-08k-Y	149,330													
	<table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th colspan="2">Disbursement</th> </tr> <tr> <th style="width: 60%;">Disbursement date</th> <th style="width: 40%;">Amount (US\$)</th> </tr> </thead> <tbody> <tr> <td>28 May, 2013</td> <td style="text-align: right;">150,000</td> </tr> <tr> <td>01 August, 2017</td> <td style="text-align: right;">149,330</td> </tr> </tbody> </table>			Disbursement		Disbursement date	Amount (US\$)	28 May, 2013	150,000	01 August, 2017	149,330				
Disbursement															
Disbursement date	Amount (US\$)														
28 May, 2013	150,000														
01 August, 2017	149,330														
11. Product switch grant:	Not applicable														
12. Indicative Annual Amounts:³	(subject to the terms of the PFA, if applicable)														
	2018-2019	2020	2021												
Type of supplies to be purchased with Gavi funds															
Number of vaccine doses		143,700	-												
Annual Amounts (US\$)	445,090	120,000	-												
13. Procurement agency:	UNICEF. The Country shall release its co-financing payments each year to UNICEF.														

¹ This is the entire duration of the programme.

² This is the total amount endorsed by Gavi for the entire duration of the programme.

³ This is the amount that Gavi has approved.

14. Self-procurement:	Not applicable																		
15. Co-financing obligations:																			
According to the co-financing policy, the Country falls within the group:	Accelerated transition																		
The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.																			
<table border="1"> <thead> <tr> <th>Type of supplies to be purchased with Country funds in each year</th> <th>2020</th> </tr> </thead> <tbody> <tr> <td>Number of vaccine doses</td> <td>224,800</td> </tr> <tr> <td>Number of AD syringes</td> <td>148,100</td> </tr> <tr> <td>Number of re-constitution syringes</td> <td>49,500</td> </tr> <tr> <td>Number of safety boxes</td> <td>2,200</td> </tr> <tr> <td>Value of vaccine doses (US\$)</td> <td>184,301</td> </tr> <tr> <td>Total co-financing payments (US\$) (including freight)</td> <td>197,000</td> </tr> <tr> <td>Minimum number of doses to be financed from domestic resources</td> <td>88,979</td> </tr> <tr> <td>Minimum amount to be financed from domestic resources (US\$)</td> <td>72,963</td> </tr> </tbody> </table>		Type of supplies to be purchased with Country funds in each year	2020	Number of vaccine doses	224,800	Number of AD syringes	148,100	Number of re-constitution syringes	49,500	Number of safety boxes	2,200	Value of vaccine doses (US\$)	184,301	Total co-financing payments (US\$) (including freight)	197,000	Minimum number of doses to be financed from domestic resources	88,979	Minimum amount to be financed from domestic resources (US\$)	72,963
Type of supplies to be purchased with Country funds in each year	2020																		
Number of vaccine doses	224,800																		
Number of AD syringes	148,100																		
Number of re-constitution syringes	49,500																		
Number of safety boxes	2,200																		
Value of vaccine doses (US\$)	184,301																		
Total co-financing payments (US\$) (including freight)	197,000																		
Minimum number of doses to be financed from domestic resources	88,979																		
Minimum amount to be financed from domestic resources (US\$)	72,963																		
In order to mitigate risks of stocking out in 2020, co-financing obligation associated with this program should be fulfilled by September 2020																			
16. Operational support for campaigns:	Not applicable																		
17. Additional Reporting Requirements:																			
<table border="1"> <thead> <tr> <th></th> <th>Due dates</th> </tr> </thead> <tbody> <tr> <td>To prepare for the annual procurement of vaccines, Country shall submit the following information each year: <ul style="list-style-type: none"> Vaccine stock levels including buffer stock, by end of March; Number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received, by mid-May. Countries shall report the actual switch date in the first renewal request following the actual implementation. </td> <td> 31 March 2020 15 May 2020 </td> </tr> <tr> <td>In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.</td> <td>To be agreed with Gavi Secretariat</td> </tr> </tbody> </table>			Due dates	To prepare for the annual procurement of vaccines, Country shall submit the following information each year: <ul style="list-style-type: none"> Vaccine stock levels including buffer stock, by end of March; Number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received, by mid-May. Countries shall report the actual switch date in the first renewal request following the actual implementation. 	31 March 2020 15 May 2020	In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Gavi Secretariat												
	Due dates																		
To prepare for the annual procurement of vaccines, Country shall submit the following information each year: <ul style="list-style-type: none"> Vaccine stock levels including buffer stock, by end of March; Number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received, by mid-May. Countries shall report the actual switch date in the first renewal request following the actual implementation. 	31 March 2020 15 May 2020																		
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Gavi Secretariat																		
18. Financial clarifications:	Not applical																		
19. Other conditions:	Not applicable																		

Signed by,

On behalf of Gavi



Thabani Maphosa,
Managing Director, Country Programmes
30-Sep-2019